A potent PfDHODH inhibitor that exhibits low nanomolar in vitro potency against DHODH from P falciparum, P vivax, and P berghei.

A potent PDE4 inhibitor with IC50 of 94.5 nM..

A potent PD-1/PD-L1 interaction inhibitor with IC50 of 80 nM in a homogenous time-resolved fluorescence binding assay..

A potent PD-1/PD-L1 interaction inhibitor with IC50 of 6-100 nM in a homogenous time-resolved fluorescence binding assay..

A potent pan-HDAC inhibitor with IC50 of 16-30 nM, inhibits cell proliferation of P815, C2, and BR cells with IC50 of 0.65, 0.30, and 0.23 uM, respectively.

A potent non-peptide antagonist of tachykinin NK2 receptor with pKi of 9.5 in CHO cells.

A potent non-nucleoside RSV L-protein polymerase inhibitor with IC50 of 89 nM.

A potent non-nucleoside RSV L-protein polymerase inhibitor with EC50 of 0.01 uM and 1.3 uM for RSV A2 and RSV B-WST, respectively.

A potent neutral endopeptidase EC 3.4.24.11 (atriopeptidase) inhibitor that increases endogenous ANF levels and produces natriuretic and diuretic responses intravenously in mice..

A potent mutant Src T338C inhibitor with IC50 of 111 nM.

A potent monoamine oxidase B (MAO-B) inhibitor..

A potent microtubule inhibitor that not only inhibits the expression levels of HIF-1α protein but also destabilizes HIF-1α mRNA.

A potent MDM2-p53 interaction inhibitor with remarkable biochemical (HTRF IC50=0.4 nM), cellular potency (SJSA-1 EdU IC50=25 nM), and favorable pharmacokinetic properties.

A potent MDM2-p53 interaction inhibitor with remarkable biochemical (HTRF IC50=0.1 nM), cellular potency (SJSA-1 EdU IC50=16 nM), and favorable pharmacokinetic properties.

A potent matrix metalloproteinase (MMP) inhibitor..

A potent lipid peroxidation inhibitor that has antishock and endothelial protective actions.

A potent Kv11.1 (hERG) channel allosteric modulator that protects cardiac tissue from hERG-related drug-induced arrhythmias.

A potent Kir7.1 inhibitor with IC50 of 2.0 uM, induces long-lasting uterine contractility similar to those observed with VU590..

A potent inwardly rectifying K+ channel Kir7.1 inhibitor with IC50 of 5.6 uM in T1+ flux assays.

A potent integrin αvβ3 antagonist with IC50 of 18 nM.

A potent inhibitor of TrkA with IC50 of 2.9 nM, also inhibits TrkB, TrkC.

A potent inhibitor of the mRNA decapping scavenger enzyme (DcpS) with IC50 of 0.11 nM.

A potent inhibitor of sEH (soluble epoxide hydrolase) with IC50 of 11.1 nM and 112 nM for mouse sEH and human sEH, respectively.

A potent inhibitor of HIV-1 integrase-LEDGF/p75 interaction.

A potent inhibitor of HDAC1/3/6 with IC50s of 43-72 nM.

A potent inhibitor of drug-resistant S31N mutant of the M2 ion channel of influenza A virus with IC50 of 153 nM.

A potent inhibitor of developmental angiogenesis in the zebrafish eye, and a cysteinyl leukotriene 1 and 2 receptor (CysLT1 and 2) antaognist with IC50 of 1.2 and 52 uM, respectively.

A potent Hsp90α/p23 interaction inhibitor with IC50 of 3.2 uM.

A potent Hsp90α/p23 interaction inhibitor with IC50 of 0.15 uM, more effective than CP-9 in degrading pAkt/total Akt and Raf-1.

A potent HIV-1 integrase strand transfer inhibitor with IC50 of 33 nM, 9.5 nM, 40 nM, 20 nM and 237 nM for wt IN, IN Y143R, IN N155H, G118R and IN G140S-Q148H, respectively.